Table 1 Clinical characteristics and Demographics of HIV-HCV coinfected patient population at Yale-New Haven Hospital HIV Clinic
Characteristic | Total patients Nâ=â219 (% or range) | Characteristic | Total patients Nâ=â219 (% or range) |
|---|---|---|---|
Age in years, median (range) | 56 (28â74) | HIV viral load <â20 copies/mL, no. (%) | 174 (80) |
Race / ethnicity, no. (%) | Â | CD4 count, median (range) | 513 (27â2060) |
âBlack | 117 (53) | On ART, no. (%) | 205 (94) |
âWhite | 68 (31) | NRTI backbone | Â |
âHispanic | 30 (14) | Tenofovir (TDF or TAF)/ emtricitabine | 135 (62) |
âOther | 4 (2) | Abacavir/ lamivudine | 47 (22) |
Gender, no. (%) | Â | NNRTI | Â |
âMale | 147 (67) | Efavirenz | 36 (16) |
âFemale | 72 (33) | Rilpivirine | 22 (10) |
HCV Genotype, no. (%) | Â | Etravirine | 10 (4.6) |
â1a | 107 (49) | Protease inhibitors/ ritonavir | Â |
â1b | 27 (12) | Atazanavir | 30 (14) |
â2 | 5 (2) | Darunavir | 31 (14) |
â3 | 6 (3) | Lopinavir | 4 (2) |
â4 | 5 (2) | Integrase inhibitors | Â |
âUnknown | 69 (32) | Dolutegravir | 51 (23) |
HCV viral load, mean IU/mL (range) | 5.83âM (15â69,000,000) | Raltegravir | 46 (21) |
Cirrhosis status, no. (%) | Â | Elvitegravir | 10 (5) |
âNon-cirrhotic | 79 (36) | Comorbidities, no (%) | Â |
âCompensated | 111 (51) | EtOH use | 184 (84) |
âDecompensated | 29 (13) | Current | 51 (23) |
HCV prior treatment, no. (%) | Â | Prior | 133 (61) |
âYes | 54 (25) | IVDU | 192 (88) |
âNo | 156 (71) | Current | 32 (15) |
âUnknown | 9 (4) | Prior | 160 (73) |
HBV Sag positive, no. (%) | 0 (0) | Psychiatric disorder | 114 (52) |
| Â | Â | *Abnormal Creatinine Clearance | 40 (18) |